PrognostiX is a next generation reference laboratory involved in the discovery, development, and commercialisation of novel biomarker technologies in the areas of cardiovascular disease, oncology, gastroenterology, inflammatory disease and neurodegenerative disease.

The CardioMPO Test is an enzyme-linked immunosorbent assay (ELISA) intended for the quantitative measurement of myeloperoxidase (MPO) in human plasma.

The CardioMPO^TM Test is composed of three different kits used together:

• CardioMPO Reagent Kit
• CardioMPO Control Kit
• CardioMPO Calibration Kit